Perrigo has entered into a definitive agreement to divest its Infant Formula business to MeridianMade for total consideration of up to $175 million, consisting of $40 million in cash at closing and up to $135 million contingent on future performance milestones through 2030. The transaction is expected to close in the first half of 2027, subject to customary conditions and regulatory approvals. Perrigo anticipates recording a non-cash impairment charge between $275 million and $375 million in the fourth quarter of 2026. This divestiture advances Perrigo's strategy to simplify its portfolio and focus on consumer self-care products. Perrigo is a leading provider of over-the-counter health and wellness solutions.
